Global (AMER, EMEA, BRICS and APAC) Oligonucleotide Therapeutics Market Size, Status and Forecast 2019-2025 (Includes Business Impact of COVID-19)

                                          
Abstract, Snapshot, Market Analysis & Market Definition: Oligonucleotide Therapeutics Market





Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies. Although several types of oligonucleotide therapies exist, five of them are compared here, including the ones targeting nucleic acids (such as mRNA) or proteins, as well as others intended for stimulation of the immune system. DDS is generally used with oligonucleotide therapy, as it is difficult for these molecules to penetrate cell membrane when administered on their own. Biogen is the industry's biggest player, with more than 76 percent of 2018 revenue, followed by Sarepta Therapeutics and Jazz Pharmaceuticals, with 13.35 percent and 6.63 percent, respectively. North America and Europe are the most important regions, accounting for more than 80 percent of the combined income. In 2018, the global Oligonucleotide Therapeutics market size was 2255.5 million US$ and it is expected to reach 7906.8 million US$ by the end of 2025, with a CAGR of 16.7% during 2019-2025. This report focuses on the global Oligonucleotide Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Oligonucleotide Therapeutics development in United States, Europe and China. 

Market Segmentation, Outlook & Regional Insights: Oligonucleotide Therapeutics Market

Segmentation by Product Type: Breakdown of data from year 2014 to 2019 and forecast until 2025:
 
Antisense Oligonucleotide
Aptamer
OtherIn 2018, antisense oligonucleotides accounted for the highest proportion of income, reaching 96.52%.

Segmentation by Application : Breakdown of data from year 2014 to 2019 and forecast until 2025:

Neuromuscular Diseases
ATTR
Hepatic VOD
OtherAccording to the application, neuromuscular diseases and hepatic VOD are the most important, accounting for 51.69% and 42.23%, respectively.
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

Key Players, Recent Developments & Sector Viewpoints: Oligonucleotide Therapeutics Market
 
Biogen
Sarepta Therapeutics
Jazz Pharmaceuticals
Bausch & Lomb
Alnylam Pharmaceuticals
Dynavax Technologies
Kastle therapeutics
Akcea Therapeutics

Key Insights Covered: Exhaustive Oligonucleotide Therapeutics Market
1.  Market size (sales, revenue and growth rate) of Oligonucleotide Therapeutics industry.
2. Global major manufacturers' operating situation (sales, revenue, growth rate and gross margin) of Oligonucleotide Therapeutics industry.
3. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Oligonucleotide Therapeutics industry.
4. Market size (sales, revenue) forecast by regions and countries from 2019 to 2025 of Oligonucleotide Therapeutics industry.

Research Methodology: Oligonucleotide Therapeutics Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request a Sample Report.
Demand Side Primary Contributors: OEMs, Industrial Professionals, Researches, Suppliers and Distributors, Group Purchasing Organizations, Associations, Insurers, Universities, Technological Writers, Scientists, Promoters, Investors among others.
Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among others.